tbuckley/cabot-search huggingface dataset:
P1.02-050 Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR-Mutant Lung Adenocarcinoma among Hispanics (Rbiop-CLICaP)
Authors: Andrés Cardona, Oscar Arrieta, Leonardo Rojas, Beatriz Wills, Noemi Reguart, Hernan Carranza, Carlos Vargas, Jorge Otero, Pilar Archila, Claudio Martin, Luis Corrales, Mauricio Cuello, Carlos Ortiz, Sandra Franco, Rafael Rosell
Journal: Journal of Thoracic Oncology (2017)
Development and validation of a UPLC–MS/MS assay for the determination of gemcitabine and its L-carnitine ester derivative in rat plasma and its application in oral pharmacokinetics
Authors: Gang Wang, Dongyang Zhao, Hongxiang Chen, Dawei Ding, Longfa Kou, Lifang Sun, Chenxia Hao, Xincong Li, Kai Jia, Qiming Kan, Xiaohong Liu, Zhonggui He, Jin Sun
Journal: Asian Journal of Pharmaceutical Sciences (2017)

A simple and rapid UPLC-MS/MS method to simultaneously determine gemcitabine and its L-carnitine ester derivative (2'-deoxy-2', 2'-difluoro-N-((4-amino-4-oxobutanoyl) oxy)-4-(trimethyl amm-onio) butanoate-cytidine, JDR) in rat plasma was developed and validated. The conventional plasma sample preparation method of nucleoside analogues is solid-phase extraction (SPE) which is time-consuming and cost-expensive. In this study, gradient elution with small particles size solid phase was applied to effectively separate gemcitabine and JDR, and protein precipitation pretreatment was adopted to remove plasma protein and extract the analytes with high recovery(>81%). Method validation was performed as per the FDA guidelines, and the standard curves were found to be linear in the range of 5-4000 ng/ml for JDR and 4-4000 ng/ml for gemcitabine, respectively. The lower limit of quantitation (LLOQ) of gemcitabine and JDR was 4 and 5 ng/ml, respectively. The intra-day and inter-day precision and accuracy results were within the acceptable limits. Finally, the developed method was successfully applied to investigate the pharmacokinetic studies of JDR and gemcitabine after oral administration to rats.
Comparison of the Performance of Multiparameter Flow-Cytometry and wt1-RNA Levels in Detecting Minimal Residual Disease and Predicting Relapse in Patients with Acute Myeloid Leukemia
Authors: Giovanni Rossi, Mariella Minervini, Angelo Michele Carella, Chiara de Waure, Lorella Melillo, Giovanni Francesco D'Arena, Nicola Cascavilla, Gina Zini
Journal: Blood (2011)
Heat Shock Protein 70 over Expression Is Associated to Imatinib Resistance in Chronic Myelogenous Leukemia.
Authors: Marion Pocaly, Valérie Lagarde, Gabriel Etienne, Jean-Antoine Ribeil, Marc Bonneu, Stéphane Claverol, François Moreau-Gaudry, Olivier Hermine, Béatrice Turcq, François-Xavier Mahon, Jean-Max Pasquet
Journal: Blood (2005)
Allergenic Food Introduction and Childhood Risk of Allergic or Autoimmune Disease—Reply
Authors: Despo Ierodiakonou, Vanessa Garcia-Larsen, Robert J. Boyle
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier
Authors: Patrice Chevallier, Pierre Peterlin, Alice Garnier, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Maud Voldoire, Thomas Gastinne, Cyrille Touzeau, Steven Le Gouill, Marie-Christine Bene, Yannick LE Bris, Philippe Moreau, Thierry Guillaume
Journal: Blood (2015)
Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML.
Authors: Sanjay R. Mohan, Paul Elson, Ramon V. Tiu, Anjali Advani, Yogen Saunthararajah, Ronald Sobecks, Matt Kalaycio, Edward Copelan, Jaroslaw P Maciejewski, Mikkael A. Sekeres
Journal: Blood (2010)
P2.01-044 Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting
Authors: Antonio Passaro, Patrizia Mancuso, Valentina Labanca, Gianluca Spitaleri, Elena Guerini-Rocco, Massimo Barberis, Sara Gandini, Cristina Noberasco, Ester Del Signore, Chiara Catania, Alessia Pochesci, Francesco Bertolini, Filippo De Marinis
Journal: Journal of Thoracic Oncology (2017)
P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
Authors: Raffit Hassan, Ross Jennens, Jan Van Meerbeeck, John Nemunaitis, George Blumenschein, Dean Fennell, Hedy Kindler, Silvia Novello, Annette Walter, Danila Serpico, Jonathan Siegel, Ariadna Holynskyj, Barrett Childs, Cem Elbi
Journal: Journal of Thoracic Oncology (2017)
Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center
Authors: Yizel Elena Paz Nuñez, Beatriz Aguado Bueno, Isabel vicuña Andrés, Ángela Figuera Álvarez, Miriam González-Pardo, Rafael de la Cámara Llanzá, Valle Gómez García de Soria, Reyes Arranz Sáez, Alvaro Arriero García, Elena Jiménez Barral, Susie Veramendi Zavala, Adrian Alegre
Journal: Blood (2015)
Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Authors: Jatin J. Shah, Donna M. Weber, Sheeba K. Thomas, Raymond Alexanian, Michael Wang, Muzaffar H. Qazilbash, Simrit Parmar, Nina Shah, Qaiser Bashir, Uday R. Popat, Brandi Hilder, Robert Z. Orlowski
Journal: Blood (2012)
Vedolizumab safety in pregnancy and newborn outcomes
Authors: Mette Julsgaard, Jens Kjeldsen, Daniel C Baumgart
Journal: Gut (2017)

We read with interest the study by Colombel et al 1 on vedolizumab (VDZ) safety in Crohn's disease (CD) and ulcerative colitis (UC). These data were derived from pivotal clinical trials which naturally exclude pregnant women, leaving this important area of pharmacovigilance unaddressed. Epidemiologically, the first age peak of IBD frequently overlaps with family planning. Thus, there is considerable interest among couples and healthcare providers on how VDZ impacts on pregnant women and newborns. Here we report the first four fully VDZ exposed and documented pregnancies and newborns.

VDZ (MLN0002, MLN02, LDP-02, anti-α4β7) is a humanised monoclonal IgG1 antibody targeting α4β7 integrin. IgG1 is the predominant means of fetal immunity and maternal–fetal transport across the placenta, which increases linearly throughout pregnancy.2 Therefore, it can …
MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)
Authors: Scott Gettinger, Jungmin Choi, Nikita Mani, Ila Datar, Edward Kaftan, Sarah Goldberg, Daniel Zelterman, Katerina Politi, Richard Lifton, David Rimm, Roy Herbst, Kurt Schalper
Journal: Journal of Thoracic Oncology (2017)
P16 Radial ebus biopsy with guide sheath for peripheral pulmonary lesions
Authors: K Srikanthan, C Drouot, B Sukumaran, V Johnson, M Walshaw, K Mohan
Journal: Thorax (2016)

<h3>Introduction</h3> The aim of lung cancer screening programs is the detection of early lung cancer, which may appear as small peripheral pulmonary lesion (PPL). Although radial EBUS guided biopsy is recommended by NICE to obtain tissue diagnosis in PPL which cannot be seen by conventional bronchoscopy, there is a paucity of published data within the UK regarding this technique. We looked at our 4-year radial EBUS results at our tertiary centre. <h3>Methods</h3> We reviewed 71 consecutive patients who underwent radial EBUS guided biopsy for investigation of a PPL, performed using a guide sheath (K201 or K203) by a consultant operator assisted by a respiratory trainee. We assessed the diagnostic rate, yield from sampling techniques (biopsy vs brushings), whether the diagnosis correlated with other procedures/management, and any complications. <h3>Results</h3> Mean patient age was 70 years (range 44–89), 38 female, and 41 (58%) had undergone 1 or more unsuccessful investigations at their local hospital. We were able to visualise the lesion by ultrasound leading to subsequent sampling in 62/71 (87 %) patients. A diagnosis of malignancy was confirmed in 41/62 (66%) patients. Of the 21 biopsies which did not demonstrate malignancy, 11 were subsequently shown to have cancer (false negatives–pathological diagnosis by other methods or clinical-radiological diagnosis or awaiting follow up) but were 10 true negative (resolution or 2 year stability on CT scan). The yield for malignancy was superior with brushings (88%) compared to biopsy (73%). The overall sensitivity for cancer was 72% (N = 71, whole cohort) and 82% (N = 62, lesion was visualised by ultrasound) respectively. Two patients developed a pneumothorax which did not require intervention. <h3>Conclusions</h3> Radial EBUS is a safe and effective technique in obtaining tissue diagnosis in PPL not amenable to other biopsy methods. We visualised the lesion in 87% of patients and our diagnostic yield for malignancy is similar to current standards. Radial EBUS should take a more prominent role in diagnostic pathways for PPL within the UK, particularly in the context of future lung cancer screening programmes.
P1.08-047 Decreasing Use of Epidural Analgesia with Increasing Minimally Invasive Lobectomy: Impact on Postoperative Morbidity
Authors: Masha Zeltsman, Alexandra Poch, Takashi Eguchi, Sarina Bains, Bernard Park, David Jones, Prasad Adusumilli
Journal: Journal of Thoracic Oncology (2017)
P1.06-016 Pulmonary Tuberculosis among Newly Diagnosed-Therapy Naive Advanced NSCLC in Persahabatan Hospital Jakarta Indonesia
Authors: Jamal Zaini, Sita Laksmi Andarini, Ririen R. Ramadhani, Elisna Syahruddin, Achmad Hudoyo
Journal: Journal of Thoracic Oncology (2017)
P2.01-037 Molecular Biology Underlying COPD and Lung Cancer Converge on FOXM1 Network
Authors: Victor Martinez, Emily Vucic, Kelsie Thu, Erin Marshall, Katey Enfield, Brenda Minatel, Sara Rahmati, Tomas Tokar, Mark Abovsky, Chiara Pastrello, Igor Jurisica, Calum Macaulay, Stephen Lam, Wan Lam
Journal: Journal of Thoracic Oncology (2017)
P2.04-004 Thymectomy without Definitive Diagnosis Could Be Feasible in Patients with Suspicious of Thymic Epithelial Tumor
Authors: Shuhei Hakiri, Koji Kawaguchi, Toshiki Okasaka, Takayuki Fukui, Koichi Fukumoto, Shota Nakamura, Naoki Ozeki, Akira Naomi, Tomoshi Sugiyama, Kohei Yokoi
Journal: Journal of Thoracic Oncology (2017)
Allogeneic Hematopoietic Stem Cell Transplantation Cures CLL: A Retrospective Analysis from the SFGM-TC Registry.
Authors: Mauricette Michallet, Quoc-Hung Lê, Jean-Paul Vernant, Franck E. Nicolini, Jean-Luc Harousseau, Philippe Colombat, Eric Deconninck, Bruno Cazin, Didier Blaise
Journal: Blood (2006)
P109 The impact of tb nice guidance on resource capacity and contact screening outcomes: a retrospective, observational study within a central london tb centre
Authors: M O’Donoghue, H Jarvis, N Drey, MH Almond, S Seneviratne, A Lalvani, OM Kon
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Recently published NICE guidance has significantly expanded the approach to adult tuberculosis (TB) contact screening by recommending tuberculin skin testing (TST) for pulmonary and laryngeal contacts only, increasing the age threshold for screening and treatment to 65 years and defining a positive TST as induration ≥5 mm, regardless of BCG vaccination status. Interferon Gamma Release Assay (IGRA) is recommended only in situations where more evidence of infection is needed. Our institution has previously adopted an approach comprising a chest radiograph, TST and IGRA. The aim of our study was to evaluate the impact of NICE guidance on screening outcomes and resource capacity by applying the criteria to a well-defined historic cohort of TB contacts. <h3>Methods</h3> This was a retrospective, observational study carried out at a central London teaching hospital. The study population comprised 593 consecutive, adult TB contacts screened between 1/1/2008 and 31/12/2010. Data was collected through a retrospective review of TST and IGRA tests. <h3>Results</h3> Of the 593 contacts screened, 358 pulmonary contacts had TST and IGRA results. 56% had a TST ≥5 mm, regardless of BCG status, qualifying them for treatment as per the new NICE guidance. Of these, 61% were IGRA negative (discordant) and may therefore include false positive diagnoses, resulting in the potential for over treatment. In those with TST 5–14 mm, discordance rises to 84%. Conversely, 6% of those with TST &lt; 5 mm are IGRA positive representing potentially missed cases. 16% of screened individuals were contacts of extra pulmonary TB. Not screening this group would reduce the demand for outpatient appointments by 151* in our cohort. In contrast, testing contacts &gt; 35 years would require capacity for an additional 165* appointments. Furthermore, there were 162 additional LTBI cases in comparison to previous guidance requiring an additional 648* appointments. 72% of this group were IGRA negative. (*Approximate) <h3>Conclusions</h3> Our results show the revised guidance will require increased resource capacity largely due to more patients being classified as having latent TB. In addition to workforce planning to meet these demands, further debate is needed to decide if this new approach truly reduces the incidence of active TB or results in unnecessary treatment.
The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice
Authors: Jessica L. Maiers, Enis Kostallari, Malek Mushref, Thiago M. deAssuncao, Haiyang Li, Nidhi Jalan‐Sakrikar, Robert C. Huebert, Sheng Cao, Harmeet Malhi, Vijay H. Shah
Journal: Hepatology (2016)

Fibrogenesis encompasses the deposition of matrix proteins, such as collagen I, by hepatic stellate cells (HSCs) that culminates in cirrhosis. Fibrogenic signals drive transcription of procollagen I, which enters the endoplasmic reticulum (ER), is trafficked through the secretory pathway, and released to generate extracellular matrix. Alternatively, disruption of procollagen I ER export could activate the unfolded protein response (UPR) and drive HSC apoptosis. Using a small interfering RNA screen, we identified Transport and Golgi organization 1 (TANGO1) as a potential participant in collagen I secretion. We investigated the role of TANGO1 in procollagen I secretion in HSCs and liver fibrogenesis. Depletion of TANGO1 in HSCs blocked collagen I secretion without affecting other matrix proteins. Disruption of secretion led to procollagen I retention within the ER, induction of the UPR, and HSC apoptosis. In wild‐type (WT) HSCs, both TANGO1 and the UPR were induced by transforming growth factor β (TGFβ). As the UPR up‐regulates proteins involved in secretion, we studied whether TANGO1 was a target of the UPR. We found that UPR signaling is responsible for up‐regulating TANGO1 in response to TGFβ, and this mechanism is mediated by the transcription factor X‐box binding protein 1 (XBP1). In vivo , murine and human cirrhotic tissue displayed increased TANGO1 messenger RNA levels. Finally, TANGO1 +/– mice displayed less hepatic fibrosis compared to WT mice in two separate murine models: CCl 4 and bile duct ligation. Conclusion : Loss of TANGO1 leads to procollagen I retention in the ER, which promotes UPR‐mediated HSC apoptosis. TANGO1 regulation during HSC activation occurs through a UPR‐dependent mechanism that requires the transcription factor, XBP1. Finally, TANGO1 is critical for fibrogenesis through mediating HSC homeostasis. The work reveals a unique role for TANGO1 and the UPR in facilitating collagen I secretion and fibrogenesis. (H epatology 2017;65:983‐998).
MA14.03 The Impact of Genomic Landscape of EGFR Mutant NSCLC on Response to Targeted and Immune Therapy
Authors: Yasir Elamin, Waree Rinsurongkawong, Hai Tran, Kathryn Gold, Jeff Lewis, Emily Roarty, Andrew Futreal, Jianjun Zhang, John Heymach
Journal: Journal of Thoracic Oncology (2017)
P3.05-008 Mindfulness-Based Stress Reduction Added to Care as Usual for Lung Cancer Patients and Their Partners: A Randomized Controlled Trial
Authors: Melanie Schellekens, Desiree Van Den Hurk, Judith Prins, A. Donders, Johan Molema, Richard Dekhuijzen, Miep Van Der Drift, Anne Speckens
Journal: Journal of Thoracic Oncology (2017)
Patterns of Lymphocyte Subsets and Index of Bone Marrow Output (KRECs) Correlate Differently with Graft-Versus-Host Disease and Relapse
Authors: Cristina Skert, Simone Perucca, Luisa Imberti, Marco Chiarini, Michele Malagola, Carla Filì, Cesare Bergonzi, Rossella Ribolla, Valeria Cancelli, Alessandro Turra, Federica Cattina, Andrea Di Palma, Domenico Russo
Journal: Blood (2014)
Paroxysmal Nocturnal Hemoglobinuria (PNH): Long Term Follow up of 48 Patients in a Single Institution.
Authors: Jefferson Ruiz, Larissa A. Medeiros, Vaneuza A.M. Funke, Carmem M.S. Bonfim, Marco A. Bitencourt, Daniela C. Setubal, Claudia Pettengil, Elenaide C. Nunes, Michel M. Oliveira, Jose Zanis Neto, Carlos R. Medeiros, Mariester Malvezzi, Ricardo Pasquini
Journal: Blood (2006)
S62 Adequacy of intra-operative lymph node sampling during surgical resection of nsclc: influencing factors and its relationship to survival
Authors: T Edwards, H Balata, C Tennyson, P Foden, P Bishop, M Jones, P Krysiak, K Rammohan, R Shah, P Crosbie, R Booton, M Evison
Journal: Thorax (2016)

<h3>Background</h3> Adequate intra-operative lymph node sampling is a fundamental part of lung cancer surgery but adherence to standards, particularly in the United Kingdom is not well known. The International Association for the Study of Lung Cancer (IASLC) has defined adequate lymph node sampling as: at least 3 mediastinal lymph node stations, station 7 in all cases, station 5/6 with left upper lobe tumours and station 9 with lower lobe tumours; the sampling of at least 3 hilar lymph node stations is also recommended This study sought to measure the adequacy of intra-operative lymph node sampling at a regional Lung Cancer Centre, the factors which may influence this and impact on survival. <h3>Methods</h3> A retrospective review of the pathological reports for all patients who underwent surgical resection for NSCLC at the University Hospital of South Manchester between 2011 and 2014 (n = 1407) was performed. Lung cancer resection specimens are reported in line with the minimum dataset defined by the Royal College of Pathology and contain a record of all lymph node stations sampled intra-operatively and the histological findings from these lymph nodes. The influence of clinical variables on adequacy of lymph node sampling was investigated and survival data was obtained from national death registries. <h3>Results</h3> Adequate intra-operative lymph node sampling increased significantly from 13% (23/173) in 2011 to 51% (224/437) in 2014 coinciding with a dramatic increase in the volume of lung cancer surgery (Table 1). Secondary analysis also revealed that patients with a low or high T-stage, undergoing sublobar resections and undergoing left sided resections have significantly higher rates of inadequate lymph node sampling. Overall, there was no statistically significant difference in survival between patients with adequate and inadequate intra-operative lymph node sampling. <h3>Conclusion</h3> This study provides a much-needed benchmark of current thoracic surgical practice in lung cancer in the UK and provides important granularity to facilitate changes to improve adequacy of staging. Further improvement is needed to meet the standards as defined by the IASLC, however, what constitutes an “acceptable” level of adequacy is yet to be defined and this impact on survival is not clear.
Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients,
Authors: Petra Jilma-Stohlawetz, Paul Knoebl, Ingrid Pabinger, James Gilbert, Robert G. Schaub, Bernd Jilma
Journal: Blood (2011)
Lowering Plasma Cholesterol by Raising LDL Receptors
Authors: Michael S. Brown, Joseph L. Goldstein
Journal: New England Journal of Medicine (1981)

More than 93 per cent of the body's cholesterol is located in cells, where it performs vital structural and metabolic functions; only about 7 per cent circulates in plasma, where it predisposes to atherosclerosis. All the cholesterol in plasma is packaged within lipoprotein particles; two thirds is in low-density lipoprotein (LDL). Epidemiologic data and animal experiments indicate that plasma LDL is a major cause of atherosclerosis, particularly in the one of every 500 members of the population who has familial hypercholesterolemia. Because of their elevated LDL levels, male heterozygotes with this dominant disease have an 85 per cent chance of . . .
Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression
Authors: Patrice Chevallier, Nelly Robillard, Marina Illiaquer, Julie Esbelin, Mohamad Mohty, Celine Bodin-Bressollette, Thierry Guillaume, Veronique Stocco, Fabienne Auffray, Sophie Derenne, Lucie Planche, Marie-christine Béné, Berthe-Marie Imbert-Marcille
Journal: Blood (2012)
P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress
Authors: Wei-Sen Lam, Y C Gary Lee, Jenette Creaney, Sanjeevan Muruganandan, Michael Millward, Catherine Read, Anna Nowak
Journal: Journal of Thoracic Oncology (2017)